
    
      This study will be conducted in a randomised, double-blind, placebo-controlled design with
      single ascending doses of SulforadexÂ® administered to healthy male subjects between 18 to 45
      years of age. Each healthy subject will receive verbal and written information followed by
      signing of the Informed Consent Form (ICF).

      Subjects will be screened within 21 days prior to admission. At this visit a medical
      examination will be performed to assess eligibility of the healthy subject. Screening will be
      conducted over 1 day or may be divided into more than 1 day. The first cohort of the study
      will commence with one sentinel group. The subsequent groups may be dosed together without
      sentinel dosing. The study is expected to have 5 cohorts with a total of 29 healthy male
      subjects:
    
  